利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.017 秒)

    Ghrelin receptor agonist for treatment of cachexia
    1.
    发明授权
    Ghrelin receptor agonist for treatment of cachexia 有权

    公开(公告)号：US10975070B2

    公开(公告)日：2021-04-13

    申请号：US13580479

    申请日：2011-02-28

    申请人： Kaoru Shimada ,  Masaki Sudo ,  Masaomi Tajimi ,  Nobuyuki Takahashi ,  Kazuhiko Nonomura

    发明人： Kaoru Shimada ,  Masaki Sudo ,  Masaomi Tajimi ,  Nobuyuki Takahashi ,  Kazuhiko Nonomura

    IPC分类号： A61K31/44 ,  C07D471/04 ,  A61K31/437 ,  A61K45/06

    摘要： The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.

    GHRELIN RECEPTOR AGONIST FOR TREATMENT OF CACHEXIA
    2.
    发明申请
    GHRELIN RECEPTOR AGONIST FOR TREATMENT OF CACHEXIA 审中-公开
    GHRELIN受体激动剂治疗慢性乙型肝炎

    公开(公告)号：US20120322821A1

    公开(公告)日：2012-12-20

    申请号：US13580479

    申请日：2011-02-28

    申请人： Kaoru Shimada ,  Masaki Sudo ,  Masaomi Tajimi ,  Nobuyuki Takahashi ,  Kazuhiko Nonomura

    发明人： Kaoru Shimada ,  Masaki Sudo ,  Masaomi Tajimi ,  Nobuyuki Takahashi ,  Kazuhiko Nonomura

    IPC分类号： A61K31/437 ,  A61P3/00 ,  C07D471/04

    CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K45/06

    摘要： The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.

    摘要翻译： 本发明涉及本发明化合物或其药学上可接受的盐或包含该化合物或其盐的药物组合物在制备用于治疗恶病质的药物中的用途。 本发明还涉及治疗恶病质的方法，其包括向人或动物施用本发明化合物或其包含该化合物的药物组合物。 本发明还涉及所述化合物或其药学上可接受的盐或包含该化合物或盐的药物组合物与一种或多种第二活性剂的组合的用途。 此外，本发明涉及药物组合物和包含本发明化合物或其药学上可接受的盐的试剂盒，用于治疗所述疾病。

    SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER
    5.
    发明申请
    SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER 有权
    选择性EP4受体激素治疗癌症的药物

    公开(公告)号：US20120088723A1

    公开(公告)日：2012-04-12

    申请号：US13265216

    申请日：2010-04-22

    申请人： Yukinori Take ,  Shinichi Koizumi ,  Takako Okumura ,  Kazuhiko Nonomura

    发明人： Yukinori Take ,  Shinichi Koizumi ,  Takako Okumura ,  Kazuhiko Nonomura

    IPC分类号： A61K31/437 ,  C07C229/38 ,  A61K38/02 ,  C07D213/82 ,  A61K31/44 ,  A61P35/00 ,  C07D471/04 ,  A61K31/195

    CPC分类号： C07D471/04 ,  A61K31/192 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4412 ,  A61K45/06 ,  C07C235/60 ,  C07D213/82

    摘要： This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

    摘要翻译： 本发明提供了用于治疗导致癌症减少的癌症的药物。 本发明涉及对前列腺素E2受体（EP4受体）具有抑制活性且由以下通式（I），（II），（III）或（IV）表示的化合物或其药学上可接受的盐 或包含该化合物或盐的药物组合物，用于制备用于治疗癌症的药物。 本发明涉及一种治疗癌症的方法，其包括将化合物或其药学上可接受的盐或包含该化合物或盐的药物组合物给予人或动物。 化合物或其药学上可接受的盐或药物组合物可以与一种或多种第二活性剂组合使用。

    USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES
    8.
    发明申请
    USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES 有权
    EP4受体拮抗剂在治疗IL-23介导性疾病中的应用

    公开(公告)号：US20120316197A1

    公开(公告)日：2012-12-13

    申请号：US13580323

    申请日：2011-02-22

    申请人： Kiyoshi Kanazawa ,  Kazuhiko Nonomura ,  Takako Okumura ,  Shinichi Koizumi

    发明人： Kiyoshi Kanazawa ,  Kazuhiko Nonomura ,  Takako Okumura ,  Shinichi Koizumi

    IPC分类号： A61K31/437 ,  C07D235/08 ,  A61K31/4184 ,  C07C235/46 ,  A61K31/195 ,  C07D405/12 ,  A61K31/443 ,  C07D409/12 ,  A61K31/41 ,  C07D333/24 ,  A61K31/381 ,  C07D213/56 ,  A61K31/44 ,  A61P37/00 ,  A61P37/08 ,  C07D471/04

    CPC分类号： A61K45/06 ,  A61K31/38 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/443 ,  A61K2300/00

    摘要： This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of immune disease or allergy in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明涉及具有EP4拮抗活性的化合物或具有EP4受体拮抗活性的药学上可接受的盐，其可用于治疗免疫疾病或变态反应。 本发明还涉及具有EP4受体拮抗活性的式（I），（II），（III），（IV），（Va）或（Vb）或其药学上可接受的盐的化合物，其可用于 治疗免疫疾病或过敏。 本发明还涉及用于治疗免疫疾病或过敏的药物组合物，其包含治疗有效量的式（I），（II），（III），（IV），（Va）或（Vb） ，或其药学上可接受的盐。 本发明还涉及一种用于治疗包括哺乳动物受试者在内的动物受试者的免疫疾病或变态反应的方法，该方法包括向包括哺乳动物受试者的动物受试者施用式（I），（II），（III ），（IV），（Va）或（Vb），或其药学上可接受的盐。